Our Take
Makary's exit creates regulatory uncertainty at a critical juncture for AI-enabled medical device approvals and digital health oversight.
Why it matters
Healthcare AI companies face potential delays or policy shifts as the FDA searches for new leadership during active guidance development on AI/ML medical devices.
Do this week
Healthcare AI teams: review pending 510(k) submissions before month-end so you can adjust regulatory strategies for potential policy changes.
Makary steps down after uncertain week
FDA Commissioner Marty Makary will resign from his position, according to a source familiar with his thinking who spoke to Endpoints News. The decision comes after days of uncertainty about Makary's job status, though specific details about the timing of his departure or the circumstances leading to his resignation remain undisclosed.
The source did not provide information about whether Makary's resignation was voluntary or requested, nor did they specify when the announcement would be made public or when his departure would take effect.
Regulatory gaps hit during AI guidance development
Makary's departure creates a leadership vacuum at the FDA during active development of artificial intelligence and machine learning guidance for medical devices. The agency has been working on updated frameworks for AI/ML-based software as medical devices, with multiple draft guidances in various stages of review.
Healthcare AI companies currently navigating the 510(k) clearance process may face delays or shifts in regulatory interpretation as interim leadership takes over. The FDA's Digital Health Center of Excellence, which oversees AI medical device approvals, operates under policies that could change with new leadership appointments.
Prepare for regulatory transition period
Companies with pending medical device applications should expect potential delays in review timelines during the leadership transition. The FDA typically maintains existing policy frameworks during interim periods, but interpretation and priority setting can shift.
Organizations planning 510(k) submissions for AI-enabled devices should accelerate their regulatory strategy reviews and consider whether to proceed under current guidance or wait for new leadership direction. The transition period could last several months depending on nomination and confirmation processes for a permanent replacement.
Healthcare AI companies should also monitor any changes in enforcement priorities or inspection schedules that might accompany the leadership change, particularly for companies with recently cleared devices under current AI/ML guidance.